The clinical architecture of this formula is deliberate — two actives, two mechanisms, one point of application, one treatment axis:

Finasteride removes the cause; minoxidil supports the recovery. Androgenetic hair loss is driven by DHT's progressive shortening of follicular growth cycles and miniaturization of hair shafts. Finasteride interrupts this hormonal driver — reducing intrafollicular DHT at the site of androgenic sensitivity with substantially lower systemic hormonal exposure than oral dosing. With the miniaturization signal reduced, follicles that retain growth capacity are freed from the progressive regression DHT was driving. Minoxidil's vasodilation, anagen prolongation, and VEGF-mediated angiogenesis then work in a hormonally more favorable follicular environment — supporting and extending the growth capacity of follicles no longer being actively suppressed by DHT.

Topical co-delivery maximizes local activity while minimizing systemic exposure. The central advantage of this formula over the traditional separate-route combination — oral finasteride plus topical minoxidil — is that both actives are delivered topically to the scalp simultaneously. Topical finasteride achieves meaningful intrafollicular DHT suppression with substantially lower systemic DHT reduction than oral dosing, preserving the anti-androgenic effect where it matters — in the scalp — while reducing systemic hormonal consequences. This makes topical co-delivery the preferred format for patients who want effective DHT suppression with a minimized systemic pharmacological footprint.

Once-nightly application supports adherence. Long-term, consistent use is the determinant of outcomes in androgenetic alopecia management. A single bedtime application covering both active mechanisms — rather than a morning oral tablet plus a separate twice-daily topical application — reduces regimen burden to its minimum, supporting the sustained adherence that produces and maintains meaningful results.

With consistent nightly application as directed by your prescribing provider:

Halt or meaningful slowing of androgenetic hair loss progression through localized intrafollicular DHT suppression

Preservation of existing hair in follicles that remain responsive, with reduced systemic hormonal exposure compared to oral finasteride

Support for hair regrowth in thinning areas through combined anti-androgenic and follicular growth-stimulating activity

Prolonged anagen (active growth) phase duration, allowing follicles to produce fuller, longer hair shafts before transitioning to resting and shedding phases

Improved perifollicular microcirculation through vasodilation and VEGF-mediated angiogenesis

Targeted scalp DHT suppression with substantially lower systemic DHT reduction compared to oral finasteride — meaningful for patients seeking localized anti-androgenic activity with reduced systemic hormonal impact

A simplified once-nightly application delivering both evidence-based hair loss mechanisms simultaneously

Sustained improvement with continued consistent use

Results vary by individual, age, pattern and stage of hair loss, and follicular reserve at treatment initiation. Meaningful improvement in density, shedding reduction, and hair shaft caliber typically develops over three to six months of consistent nightly use. Maximum benefit is generally observed at twelve months and beyond. The protective effect of finasteride reverses with discontinuation — ongoing nightly application is the clinical expectation in androgenetic alopecia management.

Apply a small amount topically to the affected areas of the scalp at bedtime.

Application Instructions:

Ensure the scalp is clean and dry before application. Evening application after showering — once hair and scalp are fully dry — is ideal.

Part the hair to expose the thinning or affected scalp regions targeted for treatment.

Apply a small amount of solution — typically 1–2 mL or as directed by your provider — directly to the affected scalp areas using the applicator or dropper, distributing evenly across the treatment zone.

Using the fingertips, thoroughly massage the solution into the scalp with gentle circular motions, ensuring even coverage and promoting absorption into the perifollicular tissue.

Allow to dry. Do not rinse. The solution should remain on the scalp overnight.

Wash hands thoroughly immediately after application. Finasteride can be absorbed through skin — hand contact with the solution must be minimized and hands must be washed promptly after each application. Women of childbearing potential must not contact the solution.

Apply remaining styling or scalp products only after the solution has fully absorbed, if applicable.

Bedtime application is strongly preferred. Overnight contact time maximizes active absorption, aligns with the skin's naturally increased nocturnal permeability, and avoids removal by daytime environmental exposure, perspiration, or styling products. Minoxidil in particular benefits from prolonged contact time with the scalp surface.

If a dose is missed: Apply when remembered on the same day, or resume the regular schedule at the next planned application. Do not double-apply to compensate for a missed dose.

Duration: Plan for a minimum three-to-six-month treatment course before assessing cosmetic response. Ongoing nightly application is the clinical expectation — results diminish if treatment is discontinued.

This is a prescription-only compounded topical medication containing finasteride. Women of childbearing potential and pregnant women must not handle this product. Full patient counseling is required before initiating therapy.

This formula is indicated for use in men. It is not appropriate for use in women or children.

Contraindications:

Women of childbearing potential and pregnant women: Finasteride is teratogenic to male fetuses — in utero exposure is associated with abnormalities of the external genitalia. Topical finasteride can be absorbed through skin contact. Women who are pregnant or may become pregnant must not apply, handle, or contact this solution in any form. This product must be stored where women of childbearing potential and children cannot access it.

Pediatric patients: Not studied or indicated in patients under 18 years of age.

Known hypersensitivity: Patients with documented allergy to finasteride, minoxidil, or any vehicle component should not use this product. A patch test on a small area of scalp before full application is recommended for patients with known scalp sensitivity.

Significant cardiovascular disease: Minoxidil retains systemic vasodilatory activity even through topical scalp application, albeit at lower absorption levels than oral dosing. Patients with significant cardiovascular conditions — heart failure, recent myocardial infarction, significant arrhythmia, or uncontrolled hypertension — should discuss the cardiovascular implications of topical minoxidil with their provider before initiating therapy.

Potential Side Effects:

Finasteride-related (topical — lower systemic exposure than oral):

Sexual side effects — decreased libido, erectile dysfunction, reduced ejaculate volume — are reported less frequently with topical than oral finasteride due to lower systemic absorption, but remain a possibility at concentrations that produce meaningful systemic absorption. Discuss with your provider promptly if experienced

Scalp irritation or contact sensitivity at the application site — less common than systemic effects but possible; discontinue and consult your provider if persistent

Local skin reactions to vehicle components — possible in patients with sensitive scalp skin

Minoxidil-related (topical):

Scalp irritation, itching, dryness, or flaking — particularly common early in treatment or in patients with sensitive scalp skin; often related to vehicle components (propylene glycol in some formulations); typically resolves or diminishes with continued use

Transient increased hair shedding during the first four to eight weeks — follicles transitioning from resting to active growth phase; expected, temporary, and a normal part of the treatment response; do not discontinue without consulting your provider

Rare contact dermatitis — persistent or worsening scalp inflammation should prompt discontinuation and provider evaluation

Rare unintended hair growth on the forehead or facial areas adjacent to application sites — minimize by applying carefully within the scalp margin and washing hands and face after application

Rare systemic cardiovascular effects from topical absorption — fluid retention, palpitations, tachycardia — more likely in patients with underlying cardiovascular conditions; report any cardiovascular symptoms promptly

Oral finasteride or dutasteride: Patients already on systemic 5-alpha reductase inhibitor therapy should inform their provider — transitioning from oral to topical finasteride or combining both requires clinical management to avoid unintended additive systemic DHT suppression.

Other topical scalp treatments: When using Hair: Finasteride / Minoxidil Solution alongside other scalp topicals — GHK-Cu scalp solution, topical spironolactone, topical ketoconazole — apply in sequence with adequate absorption time between products. Discuss all concurrent scalp treatments with your provider to optimize sequencing and avoid vehicle incompatibilities.

Antihypertensive medications: Topical minoxidil carries lower systemic vasodilatory risk than oral, but patients on antihypertensive medications should inform their provider. Additive blood pressure effects are unlikely at typical topical hair loss doses in otherwise healthy patients but warrant disclosure.

Other vasodilators: Discuss all cardiovascular medications with your provider before initiating.

Store at room temperature, 68°F – 77°F (20°C – 25°C), away from direct heat, humidity, and light

Keep container tightly closed between uses

Do not freeze

Keep strictly out of reach of women of childbearing potential and children — topical finasteride solution must not contact the skin of pregnant women or women who may become pregnant

Do not use beyond the labeled expiration date